Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Preferred Shares (2021 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Preferred Shares for 4 consecutive years, with $3.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Preferred Shares rose 63000.0% to $3.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.8 million, a 63000.0% increase, with the full-year FY2024 number at $6000.0, down 97.82% from a year prior.
  • Preferred Shares was $3.8 million for Q3 2025 at NovaBay Pharmaceuticals, up from $6000.0 in the prior quarter.
  • In the past five years, Preferred Shares ranged from a high of $3.8 million in Q3 2025 to a low of $6000.0 in Q2 2024.
  • A 4-year average of $733666.7 and a median of $449000.0 in 2023 define the central range for Preferred Shares.
  • Biggest YoY gain for Preferred Shares was 63000.0% in 2025; the steepest drop was 99.58% in 2025.
  • NovaBay Pharmaceuticals' Preferred Shares stood at $2.4 million in 2022, then plummeted by 88.56% to $275000.0 in 2023, then tumbled by 97.82% to $6000.0 in 2024, then skyrocketed by 63000.0% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for NBY's Preferred Shares are $3.8 million (Q3 2025), $6000.0 (Q2 2025), and $6000.0 (Q1 2025).